# A Safety and Tolerability Study of BDB-001 in Mild, Moderate COVID-19 Patients

> **NCT05075304** · PHASE1 · TERMINATED · sponsor: **Staidson (Beijing) Biopharmaceuticals Co., Ltd** · enrollment: 18 (actual)

## Conditions studied

- COVID-19

## Interventions

- **DRUG:** BDB-001 injection
- **DRUG:** BDB-001 injection
- **DRUG:** BDB-001 injection

## Key facts

- **NCT ID:** NCT05075304
- **Lead sponsor:** Staidson (Beijing) Biopharmaceuticals Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-02-21
- **Primary completion:** 2020-04-14
- **Final completion:** 2020-04-14
- **Target enrollment:** 18 (ACTUAL)
- **Why stopped:** Due to the COVID-19 epidemic situation, the sponsor has decided to terminate the project.
- **Last updated:** 2024-05-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05075304

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05075304, "A Safety and Tolerability Study of BDB-001 in Mild, Moderate COVID-19 Patients". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT05075304. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*